FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070403142> ?p ?o ?g. }

• W2070403142 endingPage "419" @default.
• W2070403142 startingPage "412" @default.
• W2070403142 abstract "BackgroundThe use of stereotactic ablative radiotherapy (SABR) as primary treatment for early stage non–small-cell lung cancer, or for ablation of metastases, has increased rapidly in the past decade. With local recurrence rates reported at approximately 10%, and a patient population that is becoming increasingly fit and amenable to salvage treatment, appropriate multidisciplinary follow-up care is critical. Appropriate follow-up will allow for detection and management of radiation-related toxicity, early detection of recurrent disease and differentiation of recurrence from radiation-induced lung injury.MethodsThis narrative review summarizes issues surrounding follow-up of patients treated with SABR in the context of a multidisciplinary perspective. We summarize treatment-related toxicities including radiation pneumonitis, chest wall pain, rib fracture, and fatal toxicity, and highlight the challenges of early and accurate detection of local recurrence, while avoiding unnecessary biopsy or treatment of benign radiation-induced fibrotic lung damage.ResultsFollow-up recommendations based on the current evidence and available guidelines are summarized. Imaging follow-up recommendations include serial computed tomography (CT) imaging at 3–6 months posttreatment for the initial year, then every 6–12 months for an additional 3 years, and annually thereafter. With suspicion of progressive disease, recommendations include a multidisciplinary team discussion, the use of high-risk CT features for accurate detection of local recurrence, and positron emission tomography/CT SUVmax cutoffs to prompt further investigation. Biopsy and/or surgical or nonsurgical salvage therapy can be considered if safe and when investigations are nonreassuring.ConclusionsThe appropriate follow-up of patients after SABR requires collaborative input from nearly all members of the thoracic multidisciplinary team, and evidence is available to guide treatment decisions. Further research is required to develop better predictors of toxicity and recurrence. The use of stereotactic ablative radiotherapy (SABR) as primary treatment for early stage non–small-cell lung cancer, or for ablation of metastases, has increased rapidly in the past decade. With local recurrence rates reported at approximately 10%, and a patient population that is becoming increasingly fit and amenable to salvage treatment, appropriate multidisciplinary follow-up care is critical. Appropriate follow-up will allow for detection and management of radiation-related toxicity, early detection of recurrent disease and differentiation of recurrence from radiation-induced lung injury. This narrative review summarizes issues surrounding follow-up of patients treated with SABR in the context of a multidisciplinary perspective. We summarize treatment-related toxicities including radiation pneumonitis, chest wall pain, rib fracture, and fatal toxicity, and highlight the challenges of early and accurate detection of local recurrence, while avoiding unnecessary biopsy or treatment of benign radiation-induced fibrotic lung damage. Follow-up recommendations based on the current evidence and available guidelines are summarized. Imaging follow-up recommendations include serial computed tomography (CT) imaging at 3–6 months posttreatment for the initial year, then every 6–12 months for an additional 3 years, and annually thereafter. With suspicion of progressive disease, recommendations include a multidisciplinary team discussion, the use of high-risk CT features for accurate detection of local recurrence, and positron emission tomography/CT SUVmax cutoffs to prompt further investigation. Biopsy and/or surgical or nonsurgical salvage therapy can be considered if safe and when investigations are nonreassuring. The appropriate follow-up of patients after SABR requires collaborative input from nearly all members of the thoracic multidisciplinary team, and evidence is available to guide treatment decisions. Further research is required to develop better predictors of toxicity and recurrence." @default.
• W2070403142 created "2016-06-24" @default.
• W2070403142 creator A5001581360 @default.
• W2070403142 creator A5090288280 @default.
• W2070403142 date "2015-03-01" @default.
• W2070403142 modified "2023-10-16" @default.
• W2070403142 title "Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist" @default.
• W2070403142 cites W1602534286 @default.
• W2070403142 cites W1964697240 @default.
• W2070403142 cites W1968929574 @default.
• W2070403142 cites W1969730637 @default.
• W2070403142 cites W1971386833 @default.
• W2070403142 cites W1976152125 @default.
• W2070403142 cites W1977792423 @default.
• W2070403142 cites W1980980658 @default.
• W2070403142 cites W1984955592 @default.
• W2070403142 cites W1990266033 @default.
• W2070403142 cites W1991715141 @default.
• W2070403142 cites W1991725363 @default.
• W2070403142 cites W1992228359 @default.
• W2070403142 cites W1993316229 @default.
• W2070403142 cites W1999943466 @default.
• W2070403142 cites W2012244403 @default.
• W2070403142 cites W2015063727 @default.
• W2070403142 cites W2019607817 @default.
• W2070403142 cites W2027732059 @default.
• W2070403142 cites W2030475888 @default.
• W2070403142 cites W2038905276 @default.
• W2070403142 cites W2040421594 @default.
• W2070403142 cites W2041603481 @default.
• W2070403142 cites W2042196942 @default.
• W2070403142 cites W2043853873 @default.
• W2070403142 cites W2044332607 @default.
• W2070403142 cites W2047551490 @default.
• W2070403142 cites W2050496713 @default.
• W2070403142 cites W2051021899 @default.
• W2070403142 cites W2054974480 @default.
• W2070403142 cites W2068899971 @default.
• W2070403142 cites W2071364157 @default.
• W2070403142 cites W2072729670 @default.
• W2070403142 cites W2075702041 @default.
• W2070403142 cites W2082262607 @default.
• W2070403142 cites W2083165606 @default.
• W2070403142 cites W2088901883 @default.
• W2070403142 cites W2089413503 @default.
• W2070403142 cites W2092959252 @default.
• W2070403142 cites W2094422209 @default.
• W2070403142 cites W2094862518 @default.
• W2070403142 cites W2096775754 @default.
• W2070403142 cites W2096904202 @default.
• W2070403142 cites W2098749060 @default.
• W2070403142 cites W2105603808 @default.
• W2070403142 cites W2115646671 @default.
• W2070403142 cites W2120213515 @default.
• W2070403142 cites W2126623894 @default.
• W2070403142 cites W2142806077 @default.
• W2070403142 cites W2142989887 @default.
• W2070403142 cites W2149069474 @default.
• W2070403142 cites W2149167014 @default.
• W2070403142 cites W2149623800 @default.
• W2070403142 cites W2151020778 @default.
• W2070403142 cites W2155070439 @default.
• W2070403142 cites W2157471875 @default.
• W2070403142 cites W2158368332 @default.
• W2070403142 cites W2159091878 @default.
• W2070403142 cites W2159746573 @default.
• W2070403142 cites W2162270345 @default.
• W2070403142 cites W2163211182 @default.
• W2070403142 cites W2165574206 @default.
• W2070403142 cites W2166065216 @default.
• W2070403142 cites W2169284260 @default.
• W2070403142 cites W2326531429 @default.
• W2070403142 cites W3022036063 @default.
• W2070403142 cites W2030086447 @default.
• W2070403142 doi "https://doi.org/10.1097/jto.0000000000000435" @default.
• W2070403142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25695219" @default.
• W2070403142 hasPublicationYear "2015" @default.
• W2070403142 type Work @default.
• W2070403142 sameAs 2070403142 @default.
• W2070403142 citedByCount "50" @default.
• W2070403142 countsByYear W20704031422015 @default.
• W2070403142 countsByYear W20704031422016 @default.
• W2070403142 countsByYear W20704031422017 @default.
• W2070403142 countsByYear W20704031422018 @default.
• W2070403142 countsByYear W20704031422019 @default.
• W2070403142 countsByYear W20704031422020 @default.
• W2070403142 countsByYear W20704031422021 @default.
• W2070403142 countsByYear W20704031422022 @default.
• W2070403142 countsByYear W20704031422023 @default.
• W2070403142 crossrefType "journal-article" @default.
• W2070403142 hasAuthorship W2070403142A5001581360 @default.
• W2070403142 hasAuthorship W2070403142A5090288280 @default.
• W2070403142 hasBestOaLocation W20704031421 @default.
• W2070403142 hasConcept C106159729 @default.
• W2070403142 hasConcept C126838900 @default.
• W2070403142 hasConcept C141071460 @default.
• W2070403142 hasConcept C143998085 @default.
• W2070403142 hasConcept C146357865 @default.

• next